Skip to content

Summit Therapeutics SMMT Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Roivant Sciences logo
Roivant SciencesROIV
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Biogen logo
BiogenBIIB
Moderna logo
ModernaMRNA
Insmed logo
InsmedINSM
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's operating lease ROU assets?
Summit Therapeutics (SMMT) reported operating lease ROU assets of $19.4M in Q1 2026.
How has Summit Therapeutics's operating lease ROU assets changed year-over-year?
Summit Therapeutics's operating lease ROU assets increased by 205.4% year-over-year, from $6.35M to $19.4M.
What is the long-term trend for Summit Therapeutics's operating lease ROU assets?
Over 5 years (2020 to 2025), Summit Therapeutics's operating lease ROU assets has grown at a 106.1% compound annual growth rate (CAGR), from $554K to $20.62M.